Solid Biosciences (SLDB) Other Non-Current Liabilities (2018 - 2024)

Solid Biosciences (SLDB) posted Other Non-Current Liabilities of $3.4 million for Q3 2024, up 3441.67% sequentially from $96000.0 in Q4 2022.

Analysis

Solid Biosciences (SLDB) Other Non-Current Liabilities (2018 - 2024) Analysis & Trends

Solid Biosciences has reported Other Non-Current Liabilities for 4 years, with the latest figure at $3.4 million in Q3 2024.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $3.4 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $3.4 million (changed N/A YoY) and the FY2022 annual result came in at $96000.0, changed N/A from the prior year.
Other Non-Current Liabilities rose to $3.4 million in Q3 2024 per SLDB's latest filing, from $96000.0 in the prior quarter.
Over five years, Other Non-Current Liabilities peaked at $3.4 million in Q3 2024 and troughed at $96000.0 in Q4 2022.
A 3-year average of $1.6 million and a median of $1.3 million in 2020 frame the typical range for Other Non-Current Liabilities.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Solid Biosciences	1.48 Bn	1.48 Bn	-

Historic Data

Download Data